tiprankstipranks
iX Biopharma Ltd. (SG:42C)
SGX:42C
Singapore Market

iX Biopharma Ltd. (42C) Share Price & Analysis

1 Followers

42C Stock Chart & Stats

Day’s RangeS$0 - S$0
52-Week RangeS$0.03 - S$0.10
Previous CloseS$0.04
Volume10.00K
Average Volume (3M)166.31K
Market Cap
S$31.50M
Enterprise ValueS$29.53M
Total Cash (Recent Filing)S$6.21M
Total Debt (Recent Filing)S$4.24M
Price to Earnings (P/E)-3.3
Beta0.39
Aug 19, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding768,317,356
10 Day Avg. Volume778,790
30 Day Avg. Volume166,306
Standard Deviation0.08
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

27.02%0.00%0.00%72.98%
27.02%
Insiders
0.00% Other Institutional Investors
72.98% Public Companies and
Individual Investors

42C FAQ

What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.03 and its highest was S$0.10 in the past 12 months.
    What is iX Biopharma Ltd.’s market cap?
    Currently, no data Available
    When is iX Biopharma Ltd.’s upcoming earnings report date?
    iX Biopharma Ltd.’s upcoming earnings report date is Aug 19, 2024 which is in 103 days.
      How were iX Biopharma Ltd.’s earnings last quarter?
      iX Biopharma Ltd. released its earnings results on Feb 05, 2024. The company reported -S$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.01.
        Is iX Biopharma Ltd. overvalued?
        According to Wall Street analysts iX Biopharma Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does iX Biopharma Ltd. pay dividends?
          iX Biopharma Ltd. does not currently pay dividends.
          What is iX Biopharma Ltd.’s EPS estimate?
          iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does iX Biopharma Ltd. have?
          iX Biopharma Ltd. has 768,317,400 shares outstanding.
            What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
            iX Biopharma Ltd. reported an EPS of -S$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of iX Biopharma Ltd.?
              Currently, no hedge funds are holding shares in SG:42C
              ---

              iX Biopharma Ltd. Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -54.44%
              12-Months-Change

              Fundamentals

              Return on Equity
              -76.96%
              Trailing 12-Months
              Asset Growth
              -29.08%
              Trailing 12-Months

              Company Description

              iX Biopharma Ltd.

              iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in Singapore, Australia, and China, of which the majority of the revenue comes from China..
              ---
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis